Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD.

• Status: Completed
• Trial end date: 2019-03-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the visual outcome, number of injections and visits, and the effect of mental status of a treat and extend regimen in managing neovascular age-related macular degeneration with intravitreal ranibizumab.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nagoya City University
• Collaborator: Novartis
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

• Signed informed consent form

• Male or female of aged 50 years or older

• Typical AMD and PCV patients

• BCVA of 24 letters or over

Exclusion Criteria:

• Total lesion area of >12 DA or >30.5 mm2

• The existence of subretinal hemorrhage area constituting ≥50% of total lesion area

• The existence of scar or fibrosis area constituting ≥50% of total lesion area

• The existence of RPE tear

• Prior treatment for wet AMD

• History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD

• The pregnant or lactating woman